Black Flame Medical Completes Tens of Millions RMB Series A Financing to Advance Precision Digital Healthcare with 3D Printing

VCBeat (WeChat: Vcbeat) has learned that Shanghai Heiyan Medical Science and Technology Co., Ltd. (“Heiyan Medical”) recently completed a Series A financing round worth tens of millions of RMB, with Shengshan Assets as the investor.

Founded in 2017 (formerly the Medical Division of Heichuan Technology), Shanghai Heiyan Medical is headquartered in Shanghai and is committed to becoming a leading domestic provider of integrated “technology & service” solutions for 3D-printed digital healthcare, encompassing the R&D of equipment, materials, and software.

Heiyan's Self-Developed 3D Printing Equipment and Materials

Heiyan Medical has currently established clinical application and innovation research centers for medical 3D printing in collaboration with dozens of Grade A tertiary hospitals. R&D personnel account for 75% of the company’s workforce, and it has filed 21 invention patents alone, thereby building a robust platform for research and development, marketing, and services. The company has successively secured investments from Zero2IPO Capital and Sinopharm Capital.

Photos of the Heiyan Medical 3D Printing Clinical Application and Innovation Research Center

Heiyan Medical’s core business is to provide precision treatment solutions for clinical practice, covering personalized preoperative planning, intraoperative navigation, customized implants, and postoperative rehabilitation. Leveraging technologies in digital medicine, 3D software, system development, 3D printing, and clinical applications, and using its In-Hospital Clinical Application and Innovation Research Center for Medical 3D Printing as a platform, the company delivers these solutions through its self-developed multi-center, distributed personalized production ERP system.

With the advancement of foundational technologies such as computer science, materials science, and imaging technology, 3D printing has been widely applied in medical fields including the design and fabrication of personalized implants, complex surgical instruments, and biological organ tissues. Its applications span major clinical specialties such as orthopedics, dentistry, plastic surgery, oncology, general surgery, and rehabilitation. The key to the successful application of 3D printing in precision medicine lies in combining clinical needs with precise three-dimensional structural design, selecting appropriate printing materials and techniques, and rapidly producing personalized medical device products with high accuracy. This enables individualized assessment and visualization of patients’ conditions, allowing physicians to formulate personalized, precise surgical plans tailored to each patient’s specific pathology.

Currently, 3D printing technology in the medical field is becoming increasingly mature both domestically and internationally. However, due to the lack of a systematic operational model, the efficiency, frequency, and scale of its application in actual clinical treatment cannot be rapidly increased. Since its inception, Heiyan Medical has adopted a dual-drive business model centered on “service” and “technology.” It believes that the main factors hindering the large-scale application of medical 3D printing technology stem from various aspects, including medical-engineering collaboration, acquisition of imaging data, payment methods, and delivery timeliness. To open up channels for integrating 3D printing technology with the healthcare industry, Heiyan Medical has deeply cultivated technical capabilities and a standardized service system for medical 3D printing. It provides hospitals with comprehensive technical service solutions and offers “personalized” 3D printing medical services to doctors and patients.

As a standing director unit of the 3D Printed Medical Devices Professional Committee under the China Association for Medical Devices Industry, and as one of the drafters of industry standards for 3D printed medical devices, Heiyan Medical is dedicated to fostering the seamless integration of 3D printing technology with the healthcare sector.

Lu Yidong, CEO of Heiyan MedicalHe expressed gratitude for the investors’ recognition and thanked existing shareholders for their continued support. 3D printing technology is not only an effective therapeutic tool for clinicians but also a close partner in clinical research. In recent years, driven by both national policies and technological advancements, the medical application of 3D printing has flourished. As an inevitable trend in personalized precision medicine, it offers substantial growth potential. Heiyan Medical is committed to providing hospitals with leading integrated digital healthcare solutions based on 3D printing, optimizing surgical plans for clinicians, improving surgical success rates, and ultimately benefiting more patients.

The General Manager of Shengshan Capital, the lead investor in this round, stated, Shengshan Asset Management firmly believes that 3D modeling will become an essential foundation for modern hospital management in the future, and that 3D printing services will emerge as the most convenient surgical tool for a large number of physicians. The firm also praised the excellent team at Heiyan Medical, upholding the principle that those who achieve great deeds do not fuss over minor details, and those who build great enterprises do not haggle over small profits. It expressed confidence that Heiyan Medical’s pragmatic team culture will drive the development and rapid clinical adoption of medical 3D printing technology, thereby providing more effective and precise treatment solutions for doctors and patients.

After three years of dedicated efforts, leveraging its core proprietary technologies, Heiyan Medical will deepen its exploration and R&D in the fields of bioprinting and 3D organ printing, unlocking greater possibilities for medical 3D printing.